One post will be with me, working on the production of UKHSA's weekly flu and COVID-19 surveillance report, influenza surveillance and vaccine evaluations. The other post will be with Anna Mensah, working on RSV surveillance and evaluations of the new RSV immunisation programmes in England.

Happy for you to share our study and glad you found it interesting

- VE in pregnant women was high and comparable to that seen in the general population.
- Maternal vaccination during and after pregnancy provided sustained protection in infants up to 6 months of age (the highest age we were able to look at within the study period) .

Grade 7 epidemiologist: https://www.healthjobsuk.com/job/v6234271

@pubhealthjobsuk @IDDjobs @PHJobsUK

Epidemiologist: http://www.ukhsa.reed.com/jobs/epidemiologist-colindale/1327-1/

Senior Epidemiologist: http://www.ukhsa.reed.com/jobs/senior-epidemiologist-ukhsa-colindale-61-colindale-ave-london-nw9-5eq/1324-1/

Overall these findings are good news, especially in the context of a recent outbreak of BA.2.86 in a care home where most residents received the Sanofi booster.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.39.2300489

There was no significant difference in the length of stay for those hospitalised with BQ.1 (median length of stay 5.2 days; 95% C.I.; 4.9-5.6 days), CH.1.1 (median length of stay 5.1 days; 95% C.I.; 4.6-5.6 days) or XBB.1.5 (median length of stay 5.2 days; 95% C.I.; 4.6-5.8 days)

Overall, this study provides evidence of the long-term duration of protection of the monovalent vaccines, suggesting individuals at lower risk of severe disease who did not receive a booster in autumn 2022 may not require regular re-vaccination.

The incremental protection conferred by the
bivalent vaccines estimated relative to those with waned immunity was 57% (95% C.I.: 48-
65%), meaning this is the added protection on top of that which those with waned immunity already have.

6/7

VE against hospitalisation with BA.4/5 or BA.2 was slightly higher for mRNA-1273 (Moderna) than BNT162b2 (Pfizer) booster vaccines at all time-points investigated, but confidence intervals overlapped.

The BA.2 analysis might be more susceptible to misclassification bias because of cases incidentally hospitalised with COVID-19 due to the higher infection rates during the periods when BA.2 predominated. This bias might explain the lower VE estimates for BA.2 in these periods.